Tekla Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Tekla Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,383	Closed	-$1.02M	–	209
2020 Q4	$1.02M	Hold	4,383	–	–	0.04%	177
2020 Q3	$960K	Buy	+4,383	New	+$1.07M	0.04%	181
2018 Q1	–	Sell	-1	Closed	–	–	191
2017 Q4	$0	Sell	1 -50,444	-100%	-$8.1M	﹤0.01%	162
2017 Q3	$8.31M	Hold	50,445	–	–	0.3%	64
2017 Q2	$6.85M	Buy	50,445 +10,097	+25%	+$1.49M	0.25%	75
2017 Q1	$7.77M	Buy	40,348 +6,993	+21%	+$1.12M	0.3%	68
2016 Q4	$4.7M	Hold	33,355	–	–	0.2%	82
2016 Q3	$4.87M	Hold	33,355	–	–	0.19%	87
2016 Q2	$3.36M	Hold	33,355	–	–	0.14%	112
2016 Q1	$4.46M	Hold	33,355	–	–	0.19%	93
2015 Q4	$6.63M	Sell	33,355 -27,903	-46%	-$6.04M	0.24%	79
2015 Q3	$9.68M	Buy	61,258 +29,460	+93%	+$7.88M	0.35%	66
2015 Q2	$13M	Hold	31,798	–	–	0.47%	45
2015 Q1	$14.6M	Buy	31,798 +22,614	+246%	+$9.75M	0.58%	43
2014 Q4	$5.16M	Buy	9,184 +2,386	+35%	+$1.36M	0.24%	71
2014 Q3	$3.56M	Buy	+6,798	New	+$3.84M	0.17%	98

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Tekla Capital Management's KPTI Position: Q1 2021 in Review

Tekla Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2021, closing a stake of 4,383 shares — an estimated $1.02M sold.

Tekla Capital Management first reported a position in KPTI in Q3 2014 and held it in 16 quarters. The position peaked at $14.6M in Q1 2015. 171 funds tracked by Wall St. Rank hold KPTI as of Q1 2021.

Tekla Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 4,383 Karyopharm Therapeutics shares in Q1 2021, an estimated $1.02M.
Tekla Capital Management first reported a position in Karyopharm Therapeutics in Q3 2014 and held it in 16 quarters.
Tekla Capital Management's Karyopharm Therapeutics position peaked at $14.6M in Q1 2015.
171 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.